Background
==========

Prostate cancer is the fourth most commonly diagnosed cancer and the ninth leading cause of cancer deaths among males in Japan \[[@B1]\]. At the moment, Japanese prostate cancer patients show higher risk characteristics compared with the patients in the United States, and the proportion of metastatic patients is still high \[[@B2],[@B3]\]. Whereas primary androgen deprivation therapy (PADT) is standard for metastatic prostate cancer, most patients progress to castration-resistant prostate cancer (CRPC) at various intervals after PADT. Prostate specific antigen (PSA) is a biomarker for diagnosis, risk classification, and monitoring of the disease. Most patients will experience a substantial decline in PSA levels, and their PSA levels may remain low or undetectable for years. Nevertheless, CRPC occurs frequently \[[@B4]\]. CRPC follows an androgen-independent state, which leads to widespread metastases. PSA progression in advanced prostate cancer indicates clinical progression in patients treated with PADT within a median of 6 months \[[@B5]\]. The substantial variability in the clinical course of metastatic prostate cancer has led to the evaluation of a number of prognostic factors with respect to their roles in determining the treatment strategy and ability to predict the response to therapy. In most clinical trials of prostate cancer, an improvement of 50% in the serum PSA is used as a marker of response \[[@B6],[@B7]\]. The criteria for disease progression when using changes in PSA is defined by the Prostate Cancer Clinical Trials Working Group (PCWG2) \[[@B6]\] and the Prostate-Specific Antigen Working Group (PSAWG) \[[@B7]\], and has been validated by the data-sets from two large Southwest Oncology Group Trials (SWOG 9346 and 9916) \[[@B8]\]. We endeavored to identify risk factors for prognosis in our series of patients with hormone naïve metastatic prostate cancer.

Methods
=======

This study retrospectively evaluated 286 Japanese patients with metastatic prostate cancer who received PADT following diagnosis in the Nara Uro-Oncology Research Group (NUORG) between January 1998 and December 2005. The diagnosis was based on prostate biopsy. Abdominal computed tomography and/or bone scans were used in all cases with suspected metastases. All patients were treated with PADT using a luteinizing hormone-releasing hormone (LH-RH) agonist, surgical castration, anti-androgen monotherapy or combined androgen blockade (CAB).

Follow-up data were retrieved from the hospital medical records. Patients were followed every month for the first 3 months and every 3 months thereafter. The nadir PSA level was defined as the lowest PSA level after PADT. CRPC was defined as the first day when the PSA was increased for three consecutive times or when clear clinical radiological evidence of progressive disease was shown. This study analyzed the incidences of progression times to CRPC after the initiation of PADT and overall survival time. The progression rate to CRPC and overall survival rate were estimated and both univariate and multivariate analyses were carried out to determine the prognostic value of age (≤75 years vs. ≥76 years), TNM classification (UICC 2002 \[[@B9]\]), pathological Gleason score (6--8 vs. 9--10), PSA level at diagnosis (\<100 ng/mL vs. 100--500 ng/mL vs. ≥500 ng/mL), nadir PSA level (\<0.2 ng/mL vs. 0.2-4 ng/mL vs. ≥4 ng/mL), time from PADT to nadir (≥12 months vs. 6--12 months vs. \<6 months) and time from PADT to CRPC (No occurrence of CRPC vs. ≥12 months vs. 6--12 months vs. \<6 months).

Statistical analyses were carried out using the SPSS software package (SPSS Inc., Chicago, Illinois, version 17.0) and p \< 0.05 was considered to be statistically significant. Overall survival was estimated by the Kaplan-Meier method. The log rank test was used to assess differences between groups. The Cox proportional hazards regression model was performed to analyze independent predictors of CRPC and overall survival. Only the variables that were found to be significant in the univariate analyses (p \< 0.05) were entered into the multivariate analysis to determine the most significant factor for predicting disease outcome.

The Medical Ethics Committee of Nara Medical University approved this retrospective study, and it was exempted to obtain informed consent from the patients in consideration of the aim and methods of this study.

Results
=======

The characteristics of the patients are shown in Table [1](#T1){ref-type="table"}. The median age and PSA at diagnosis were 73 years (range 50 to 92) and 174 ng/mL (range 5.7 to 21864), respectively. The median follow-up was 47 months (range 2 to 128) and the treatment of PADT was CAB in 92.0% of the patients. There were no differences in the progression time to CRPC and overall survival between PADTs (LH-RH agonist, surgical castration, anti-androgen monotherapy or CAB) (Data are not shown). Most patients initially responded to PADT. The median nadir PSA level was 0.3 ng/mL (range 0.001 to 650) and 42.7% of patients reached a nadir PSA \<0.2 ng/mL. The median time from PADT to nadir was 9.45 months (range 1 to 64). 72.4% of patients progressed to CRPC and the median time to progression after the initiation of treatment was 13 months (range 1 to 97). The 5-year overall survival rate was 63.0%, the median survival time from CRPC was 45 months, and 35.7% of patients died during the follow-up period, of which cancer deaths and other cause deaths were 27.6% and 8.0%, respectively.

###### 

Characteristics of patients and the results of the log-rank test of prognostic factors

                                       **Median (range)**   **No. of patients**   **No. of CRPC**   **Median progression time (months)**                        **No. of deaths**   **Median survival time (months)**      
  ------------------------- --------- -------------------- --------------------- ----------------- -------------------------------------- -------------------- ------------------- ----------------------------------- --------
  Total                                                             286                 207                          19                                                102                         113                     
  Age                                     73 (50--91)                                                                                                                                                                      
                            ≤75                                     179                 132                          19                                                69                          85                      
                            ≥76                                     107                 75                           18                           n.s.                 33                         none                   n.s.
  T                         T1                                       4                   2                           57                    \*(T2 vs. T3, T4)            0                       all alive                  
                            T2                                      31                  18                           37                            9                   111                                             
                            T3                                      162                 114                          19                            60                  83                                              
                            T4                                      89                  73                           14                            33                  77                         n.s.                 
  N                         N0                                      164                 116                          19                                                59                          79                      
                            N1                                      122                 91                           19                           n.s.                 43                          99                    n.s.
  M                         M0                                      50                  31                           26                                                 9                          99                      
                            M1                                      236                 176                          18                           n.s.                 93                          83                    n.s.
  Gleason score             6-8                                     181                 83                           21                            \*                  63                          115                     
                            9-10                                    105                 124                          14                            39                  85                         n.s.                 
  PSA at diagnosis                      174 (5.7-21864)                                                                                                                                                                    
                            \<100                                   105                 64                           23                    \*(\<100 vs. ≥500)          31                          85                      
                            100-500                                 97                  73                           16                            36                  113                                             
                            ≥500                                    84                  70                           15                            35                 none                        n.s.                 
  Nadir PSA level                       0.3 (0.001-650)                                                                                                                                                                    
                            \<0.2                                   122                 71                           38                           \*\*                 26                          115                  \*\*\*
                            0.2-4                                   112                 86                           13                            44                  62                                              
                            ≥4                                      52                  50                           8                             32                  25                                              
  Time from PADT to Nadir                 9.45 (1--64)                                                                                                                                                                     
                            ≥12                                     114                 74                           35                           \*\*                 23                          113                  \*\*\*
                            6-12                                    83                  62                           13                            39                  79                                              
                            \<6                                     89                  71                           7                             40                  28                                              
  Time from PADT to CRPC                   13 (1--97)                                                                                                                                                                      
                            No CRPC                                 79                                                                                                 14                         none                     
                            ≥12                                     112                                                                                                32                          113                  \*\*\*
                            6-12                                    63                                                                                                 34                          35                      
                            \<6                                     32                                                                                                 22                          21                      

\*P\<0.005, \*\*all P\<0.001, \*\*\*P\<0.001 without No CRPC vs. ≥12

PADT: primary androgen deprivation therapy.

CRPC: castration resistant prostate cancer.

T stage (T2 vs. T3, T4), Gleason score (6--8 vs. 9--10), PSA at diagnosis (\<100 ng/mL vs. ≥500 ng/mL), nadir PSA (\<0.2 ng/mL vs. 0.2-4 ng/mL) and time from PADT to nadir (≥12 months vs. 6--12 months vs. \<6 months) were significantly associated with the progression time to CRPC (Table [1](#T1){ref-type="table"}). A lower nadir PSA level and a longer time from PADT to nadir were associated with a lower proportion of patients with CRPC progression. The median progression time to CRPC of the patients with nadir PSA \<0.2 ng/mL, 0.2-4 ng/mL and ≥4 ng/mL were 38 months, 13 months and 8 months, respectively (p \< 0.005). The median progression time to CRPC of the patients whose time from PADT to nadir were ≥12 months, 6-12 months and \<6 months, were 35 months, 13 months and 7 months, respectively (p \< 0.005). The median nadir PSA level of the patients with time from PADT to nadir ≥12 months, 6--12 months and \<6 months, were 0.1 ng/mL, 0.3 ng/mL and 1.18 ng/mL, respectively (p \< 0.05: ≥12 months vs. \<6 months). The univariate analysis showed that the Gleason score, PSA at diagnosis, nadir PSA and time from PADT to nadir were associated with progression to CRPC (Table [2](#T2){ref-type="table"}). The multivariate analysis showed that Gleason score, nadir PSA and time from PADT to nadir were significant independent factors.

###### 

Hazards ratio estimate and confidence intervals from proportional hazards modeling of progression to CRPC

                                       **Univariate analysis**   **Multivariate analysis**                                  
  ------------------------- --------- ------------------------- --------------------------- --------- ------- ------------- ---------
             Age                                0.993                   0.975-1.011           0.425    0.990   0.972-1.007    0.248
              T                T1                 1                                                                              
                               T2               1.359                   0.315-5.867           0.681                              
                               T3               2.142                   0.528-8.691           0.286                              
                               T4               3.336                  0.816-13.647           0.094                              
        Gleason score          6-8                1                                                      1                       
                              9-10              1.518                   1.148-2.009           0.003    1.362   1.023-1.813    0.034
      PSA at diagnosis        \<100               1                                                      1                       
                             100-500            1.374                   0.981-1.923           0.064    0.990   0.691-1.417    0.955
                              ≥500              1.616                   1.149-2.271           0.006    1.099   0.682-1.492    0.965
       Nadir PSA level        \<0.2               1                                                      1                       
                              0.2-4             2.778                   2.011-3.836          \<0.001   2.794   1.984-3.936   \<0.001
                               ≥4               6.339                   4.315-9.313          \<0.001   6.332   4.066-9.861   \<0.001
   Time from PADT to nadir     ≥12                1                                                      1                       
                              6-12              2.091                   1.480-2.953          \<0.001   2.245   1.559-3.232   \<0.001
                               \<6              4.131                   2.956-5.774          \<0.001   4.408   3.099-6.271   \<0.001

95% CI.: 95% confidence interval.

PADT: primary androgen deprivation therapy.

CRPC: castration resistant prostate cancer.

The log-rank test showed that overall survival was correlated with nadir PSA (\<0.2 ng/mL vs. 0.2-4 ng/mL vs. ≥4 ng/mL), time from PADT to nadir (≥12 months vs. 6--12 months vs. \<6 months) and time from PADT to CRPC (≥12 months vs. 6--12 months vs. \<6 months) (Table [1](#T1){ref-type="table"}). The multivariate analysis showed that nadir PSA and time from PADT to nadir were independent factors associated with overall survival (Table [3](#T3){ref-type="table"}).

###### 

Hazards ratio estimate and confidence intervals from proportional hazards modeling of overall survival

                                       **Univariate analysis**   **Multivariate analysis**                                  
  ------------------------- --------- ------------------------- --------------------------- --------- ------- ------------- ---------
             Age                                0.987                   0.962-1.013           0.324    0.994   0.967-1.021    0.647
       Nadir PSA level        \<0.2               1                                                      1                       
                              0.2-4             3.038                   1.852-4.982          \<0.001   2.329   1.342-4.040    0.003
                               ≥4                 7                    4.109-11.925          \<0.001   5.221   2.757-9.889   \<0.001
   Time from PADT to nadir     ≥12                1                                                      1                       
                              6-12              2.544                   1.473-4.393           0.001    1.483   0.789-2.789    0.221
                               \<6              6.918                  4.174-11.467          \<0.001   4.008   2.137-7.517   \<0.001
   Time from PADT to CRPC    No CRPC              1                                                      1                       
                               ≥12              0.963                   0.509-1.822           0.907    0.718   0.367-1.407    0.335
                              6-12              4.323                   2.310-8.089          \<0.001   1.419   0.664-3.031    0.367
                               \<6              9.021                  4.570-17.808          \<0.001   1.712   0.731-4.005    0.215

95% CI.: 95% confidence interval.

PADT: primary androgen deprivation therapy.

CRPC: castration resistant prostate cancer.

Discussion
==========

A PSA test provides useful information, not only for the screening of prostate cancer but also for monitoring following treatment. Moreover, PSA monitoring before and after PADT are useful to evaluate the response to treatment in patients with prostate cancer. PSA concentrations decrease by 80% in approximately 80% of patients in the first month following PADT \[[@B10]\], and normalize in 95% of cases within 3--6 months \[[@B11]\]. Rising PSA after the nadir value under PADT represents the first objective sign of CRPC. PSA recurrence usually predates clinical progression of metastatic prostatic cancer after PADT \[[@B6],[@B12]\]. Most of the patients in the current series initially responded to PADT; 43.2% of patients reached a nadir PSA \<0.2 ng/mL, 72.4% had progression to CRPC and the median time from PADT to CRPC was 13 months.

We sought to identify risk factors for the prognosis of a series of patients with metastatic prostate cancer before or during PADT. We believe that it could be useful to decide on the best treatment strategy to predict which patients are more likely to develop early progression to CRPC. There are many views about the prognostic value of the PSA level at diagnosis. Several PSA-related parameters have been reported, including PSA at diagnosis, pattern of PSA decrease after treatment, time to nadir PSA and percentage of PSA decrease. Some authors found that the PSA level at diagnosis did not predict the time to progression \[[@B5],[@B13]\]. However, others have proposed that PSA at diagnosis predicts the disease response to androgen suppression \[[@B14]-[@B16]\]. Early normalization of PSA delays the time to progression, and in combination with the Gleason score, PSA is an important prognostic factor to predict the efficacy of the therapy \[[@B17]\]. The decline of PSA to \<4 ng/mL after the initiation of PADT within 3 months is thought to be more important than the Gleason score in determining the time to progression \[[@B17]\].

Nadir PSA after PADT is usually evaluated in relation to progression to CRPC \[[@B13],[@B16],[@B18]-[@B21]\]. The ability to achieve an undetectable PSA level as nadir is the most significant predictor of the time to CRPC for metastatic and advanced prostatic cancer and the time to nadir PSA is significantly and positively correlated with the PSA progression-free survival \[[@B13]\]. Failure to attain a nadir PSA of \<1 ng/mL after treatment predicts early progression to CRPC \[[@B20],[@B21]\]. In the current series, the median nadir PSA level was 0.3 ng/mL. We classify the nadir PSA level into \<0.2 ng/mL, 0.2-4 ng/mL and ≥4 ng/mL, because PSA level \<0.2 ng/mL is an undetectable PSA and the normal PSA value is less than 4 ng/mL. Then, nadir PSA (\<0.2 ng/mL vs. 0.2-4 ng/mL vs. ≥4 ng/mL) was a significant independent factor that predicted the progression to CRPC after PADT.

Nadir PSA levels after PADT are usually evaluated in relationship to the overall survival time. A nadir PSA of \>2 ng/mL predicts poorer overall survival \[[@B21]\]. By using the data of a randomized phase 3 trial, a PSA level of ≤4 ng/mL after 7 months of PADT was a strong independent predictor of improvement survival in metastatic hormone-sensitive prostate cancer \[[@B22]\]. Time to nadir \< 6 months, Gleason score \>7 and nadir PSA ≥0.2 ng/mL independently predicted shorter overall survival in patients with metastatic hormone-sensitive prostate cancer \[[@B18]\], which included patients who underwent definitive initial local therapy (radical prostatectomy or radiotherapy) and did not showed the factor of time to CRPC after initiation of PADT. Nadir PSA \<0.2 ng/mL and longer time to nadir (\>9 months) during PADT are the most important early predictors for survival in prostate cancer patients with bone metastasis \[[@B23]\]. The current study included the metastatic prostate cancer patients treated only with PADT, also predicts the factor of progression to CRPC and showed a nadir PSA (\<0.2 ng/mL vs. 0.2-4 ng/mL vs. ≥4 ng/mL) and the time from PADT to nadir (≥12 months vs. 6--12 months vs. \<6 months) were independent factors for overall survival. Nadir PSA and time from PADT to nadir are important factors associated with both CRPC and overall survival. This indicates that a simple measurement of PSA was strongly associated with time to CRPC and overall survival in metastatic CRPC, and the optimal cut-off point of the nadir PSA and the time from PADT to nadir predicts a short or long response of PADT.

Longer time to reach nadir PSA was associated with a lower nadir PSA level and this may simply indicate continued androgen sensitivity. The mechanisms responsible for the association of shorter time to nadir with a worse prognosis are not clear. A rapid decrease in the PSA level may be related to a transcriptional effect of PADT on PSA progression rather than prostate cancer cell death \[[@B20]\]. A rapid decrease in the PSA level after PADT may be due to ablation of the androgen receptor function, and quick suppression of androgen/androgen receptor during PADT may have a negative effect on disease progression, because the androgen receptor can act as a tumor suppressor for prostate cancer \[[@B24]\]. Another possibility is that a rapid removal of hormone-sensitive prostate cancer cells may induce an environment that allows the growth of hormone-resistant prostate cancer cells \[[@B23]\].

There are limitations to the current study. Firstly, some important factors, such as lactate dehydrogenase, alkaline phosphatase, albumin, testosterone, hemoglobin and performance status were not included in this analysis, because they were not routinely measured in the patients. Secondly, we only reported the outcomes of PADT but not evaluated the following results of second-line treatment such as chemotherapy. Thirdly, there may be interobserver variation of the Gleason score between general pathologists and uropathologists.

Conclusions
===========

PSA progression and PSA decline provide clinically meaningful information early during the treatment course of patients with metastatic prostate cancer who are unlikely to benefit from standard PADT long before they develop CRPC. Further prospective data and external validation of independent datasets are needed to confirm these findings.

Lower nadir PSA value and longer time to nadir PSA after the initiation of PADT correlate with lower progression to CRPC and higher overall survival.
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